Horizon Health International Corp.

January 05, 2011 14:51 ET

Horizon Health International Corp. Announces Resignation of the Chairman of the Board

MONTREAL, QUEBEC--(Marketwire - Jan. 5, 2011) - HORIZON HEALTH INTERNATIONAL CORP. (PINK SHEETS:HZHID) (the Company) announced today that the Company's Chairman of the Board, Dr. Max Arella of Montreal QC tendered his resignation on December 31, 2010.

Dr. Arella stated: "My resignation is due to the various previous commitments I have in other companies and also in teaching activities that I am planning during the next few months. However, I will always be available to help you in the scientific and business discussions with our partner in Japan. I have enjoyed very much our collaboration and I am looking forward to serve the company when you may need my advice."

Mr. Rocco Di Fruscia, the Company's CEO, stated, "I regret, but understand the decision by Dr. Arella. We thank Dr. Arella and look forward to work with him in an advisory capacity when required from time to time."

About Horizon Health International Corp.

HORIZON's subsidiary 'New Release Lactoferrin Pharma Canada Inc.' is an emerging specialty pharmaceutical company that is committed to supply its patented delivery systems of enteric lactoferrin, and "PEG-lactoferrin". We have already introduced enteric lactoferrin products in the market as a supplemental food and have also undertaken projects to further study these products and increase their pharmaceutical applications. Since 2008, the company's proprietary enteric lactoferrin has already earned top market share amongst all lactoferrin-containing products.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the Company's products, increased levels of competition, new products and technological changes, dependence upon third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic reports.

Contact Information